These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3413 related articles for article (PubMed ID: 7309294)

  • 1. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.
    Cochran AJ; Buyse ME; Lejeune FJ; Macher E; Revuz J; Rümke P
    Int J Cancer; 1981 Nov; 28(5):543-50. PubMed ID: 7309294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
    Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
    Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
    Abdi EA; Hanson J; McPherson TA
    Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.
    Quirt IC; Shelley WE; Pater JL; Bodurtha AJ; McCulloch PB; McPherson TA; Paterson AH; Prentice R; Silver HK; Willan AR
    J Clin Oncol; 1991 May; 9(5):729-35. PubMed ID: 2016615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness.
    Morton DL; Davtyan DG; Wanek LA; Foshag LJ; Cochran AJ
    Cancer; 1993 Jun; 71(11):3737-43. PubMed ID: 8490924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant BCG immunotherapy for malignant melanoma.
    Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
    Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
    Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
    J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
    Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
    J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
    Fairbairn NG; Orfaniotis G; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
    Crocetti E; Mangone L; Lo Scocco G; Carli P
    Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide.
    Elias EG; Suter CM; Fabian DS
    J Surg Oncol; 1997 Jan; 64(1):17-22. PubMed ID: 9040795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 171.